



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

August 10, 2020

Christopher C. Schreiber  
Executive Chairman of the Board  
Akers Biosciences, Inc.  
201 Grove Road  
Thorofare, New Jersey 08086

**Re: Akers Biosciences, Inc.**  
**Definitive Proxy Statement on Schedule 14A**  
**Filed July 29, 2020**  
**Preliminary Proxy Statement on Schedule 14A**  
**As Amended July 23, 2020**  
**File No. 001-36268**

Dear Mr. Schreiber:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Rick Werner, Esq.